Frequently Asked Questions
The market is segmented based on , By Method (ELISA, Point of Care Testing, Enzymatic Assay, Colorimetric Assay, and Others), Product Type (Instruments, Testing Kits, and Reagent), Disease Type (Type 1 Diabetes, Type 2 Diabetes, and Gestational Diabetes), End-Users (Hospitals, Homecare, Specialty Clinics, and Others), Distribution Channel (Hospital Pharmacy, Online Pharmacy, and Retail Pharmacy) – Industry Trends and Forecast to 2031.
.
The Global Diabetic Assays Market size was valued at USD 3.38 USD Billion in 2023.
The Global Diabetic Assays Market is projected to grow at a CAGR of 4.5% during the forecast period of 2024 to 2031.
The major players operating in the market include Abbvie, Inc (U.S.), Novartis AG (Switzerland), Teva Pharmaceutical Industries Ltd (Israel), Pfizer Inc. (U.S.), Merck KGaA (U.S.), Abbott (U.S.), Siemens Healthcare Private Limited (Germany), Dynatronics Corporation (U.S.), BIOMÉRIEUX (France), Bio-Rad Laboratories, Inc. (U.S.), BAG Diagnostics GmbH (Germany), DiaSorin S.p.A. (Italy), DRG INSTRUMENTS GMBH (Germany), PTS Diagnostics (U.S.), Ortho Clinical Diagnostics (U.S.), Diazyme Laboratories, Inc. (U.S.), ETHOS BIOSCIENCES (U.S.), Abnova Corporation (Taiwan), and Monobind Inc. (U.S.).
The market report covers data from the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America..
